Adverse Outcomes Are Increased with Exposure to Added Combinations of Infant Vaccines
DOI:
https://doi.org/10.56098/xfzkf650Keywords:
infant vaccine combinations, adverse effects, adverse outcome discovery, DTaP, suspected infection, rotavirus vaccine, polio vaccine, pneumococcal vaccine, HIB vaccine, developmental disorders, developmental diseases, respiratory disease, hepatitis B vaccineAbstract
This study evaluates 1,542,076 vaccine combinations administered to infants (less than 1 year of age at time of vaccination) between July 1st, 1991 and May 31st, 2011. All patients received a minimum of DTaP, HIB, and IPV at each administration (Base N=227,231). Vaccines additionally administered form the 7 cohorts of this study: HepB (N=321,296); PNC (pneumococcal) (N=319,420); Rota (N=10,139); HepB-PNC (N=531,516); HepB-Rota (rotavirus)(N=22,800); PNC- Rota (N=35,882); HepB-PNC-Rota (N=73,792). We produce a systematic analysis of the 7 cohorts and discover adverse outcomes associated with vaccine combinations, as well as describe adverse trends based on the increasing number of vaccines administered. All findings reported meet the highest bar of scientific scrutiny, p- value<0.0001 post-Bonferroni correction. This study’s analysis is limited to diagnoses made within 30-days of vaccination (excluding day-of vaccination) of respiratory, developmental, and suspected infections.
References
Burnett, E., Parashar, U., & Tate, J. (2018). Rotavirus vaccines: Effectiveness, safety, and future directions. Paediatric Drugs, 20(3), 223–233. https://doi.org/10.1007/s40272-018-0283-3
Fortunato, F., Martinelli, D., Lopalco, P. L., & Prato, R. (2022). Safety evaluation of the dtap5-ipv-hib-hepb vaccine: A review. Expert Opinion on Drug Safety, 21(3), 295–302. https://doi.org/10.1080/14740338.2022.2007882
Gagneur, A., Nowak, E., Lemaitre, T., Segura, J.-F., Delaperrière, N., Abalea, L., Poulhazan, E., Jossens, A., Auzanneau, L., Tran, A., Payan, C., Jay, N., De Parscau, L., & Oger, E. (2011). Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study. Vaccine, 29(21), 3753–3759. https://doi.org/10.1016/j.vaccine.2011.03.035
Gagneur, A., Pinquier, D., & Quach, C. (2015). Immunization of preterm infants. Human Vaccines & Immunotherapeutics, 11(11), 2556–2563. https://doi.org/10.1080/21645515.2015.1074358
Mayr, F. B., Yende, S., & Angus, D. C. (2014). Epidemiology of severe sepsis. Virulence, 5(1), 4–11. https://doi.org/10.4161/viru.27372
Mijatovic-Rustempasic, S., Immergluck, L. C., Parker, T. C., Laghaie, E., Mohammed, A., McFadden, T., Parashar, U. D., Bowen, M. D., & Cortese, M. M. (2017). Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix®. Human Vaccines & Immunotherapeutics, 13(4), 928–935. https://doi.org/10.1080/21645515.2016.1255388
Pinkbook: Hepatitis B | cdc. (2022, September 21). https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html
Pinkbook: Pneumococcal disease | cdc. (2022, September 21). https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
Roué, J.-M., Nowak, E., Le Gal, G., Lemaitre, T., Oger, E., Poulhazan, E., Giroux, J.-D., Garenne, A., & Gagneur, A. (2014). Impact of rotavirus vaccine on premature infants. Clinical and Vaccine Immunology: CVI, 21(10), 1404–1409. https://doi.org/10.1128/CVI.00265-14
Wodi, A. P. (2024). Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger—United states, 2024. MMWR. Morbidity and Mortality Weekly Report, 73. https://doi.org/10.15585/mmwr.mm7301a2
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Karl Jablonowski, Brian Hooker
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.